Abbott Laboratories

ABT · NYSE · USD

$96.81+0.12%+$0.12

Close · October 2, 2026

At a glance

Revenue growth: +5.67%; 2025 vs 2024
Net income growth: −51.32%; 2025 vs 2024
Net margin: 14.7%; 2024: 31.9%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total assets	86,713	81,414	73,214	74,438	75,196	72,548	67,887	67,173	76,250	52,666
Current assets	25,996	23,656	22,670	25,224	24,239	20,441	15,667	14,632	20,147	26,776
Cash and equivalents	8,522	7,616	6,896	9,882	9,799	6,838	3,860	3,844	9,407	18,620
Short-term investments	417	351	383	288	450	310	280	242	203	155
Receivables	7,929	6,925	6,565	6,218	6,487	6,414	5,425	5,182	5,249	3,248
Inventory	6,488	6,194	6,570	6,173	5,157	5,012	4,316	3,796	3,601	2,434
Net property, plant and equipment	12,942	11,733	11,276	10,278	10,112	10,130	8,972	7,563	7,607	5,705
Goodwill	24,035	23,108	23,679	22,799	23,231	23,744	23,195	23,254	24,020	7,683
Other intangible assets	5,526	6,647	8,815	10,454	12,739	14,784	17,025	18,942	21,473	4,539
Long-term investments	595	573	485	468	512	665	585	590	520	2,955
Current liabilities	16,496	14,157	13,841	15,489	13,105	11,907	10,863	9,012	8,912	6,660
Accounts payable	4,240	4,195	4,295	4,607	4,408	3,946	3,252	2,975	2,402	1,178
Long-term debt	9,896	12,676	13,694	14,522	17,296	18,527	16,661	19,359	27,210	20,681
Total debt	14,136	15,326	15,968	17,966	19,251	19,677	18,898	19,366	27,718	21,138
Total liabilities	33,942	33,513	34,387	37,533	39,172	39,545	36,586	36,451	45,152	31,949
Total equity (incl. minority)	52,771	47,901	38,827	36,905	36,024	33,003	31,301	30,722	31,098	20,717
Retained earnings	49,781	47,261	37,554	35,257	31,528	27,627	25,847	24,560	23,978	25,565
Minority interest	641	237	224	219	222	219	213	198	201	179